The present communication provides a survey of the state of art in antitumour drug therapy. Beside the appearance of new drugs for the treatment of human malignant diseases a remarkable progress has been witnessed in the elucidation of their mode of action. The accumulated data from studies on the mode of action of the cytostatic agents could be exploited in the clinical settings. Noteworthy is the application of those agents which could circumvent the toxic side effects of the cytostatic agents. Nevertheless to utilize the therapeutic potential of the cytostatic agents the dose adaptation should rely on pharmacokinetic estimates of the drug in the human body before starting the treatment schedide. It is highly probable that the application of modulator agents will augment the therapeutic efficacy of some agents as it is shown with 5-ethyl-2'deoxyuridine which could improve the selective antitumour action of 5-fluorouracil. On the opposite certain pharmaceutical agents i.e. pentoxifyllin, could deteriorate the antitumour action of the cytostatic agents by disturbing the checkpoint control mechanism at the G2 phase of cell cycle. It is highly probable that cytostatic agents will represent a subtantial tool in the complex antitumour therapy in the future as well, however, to give way for their therapeutic potential the pharmacobiochemical and pharmacokinetic determinants of their efficacy should be estimated before starting therapy.
|Translated title of the contribution||Changing strategy and increasing possibilities in the cytostatic therapy of cancers|
|Number of pages||8|
|Publication status||Published - Dec 1 1999|
ASJC Scopus subject areas